| Sensitive tumour detection and classification using plasma cell-free DNA methylomes SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ... Nature 563 (7732), 579-583, 2018 | 701 | 2018 |
| Akt phosphorylation and gefitinib efficacy in patients with advanced non–small-cell lung cancer F Cappuzzo, E Magrini, GL Ceresoli, S Bartolini, E Rossi, V Ludovini, ... Journal of the National Cancer Institute 96 (15), 1133-1141, 2004 | 455 | 2004 |
| Mass spectrometry to classify non–small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a … F Taguchi, B Solomon, V Gregorc, H Roder, R Gray, K Kasahara, ... Journal of the National Cancer Institute 99 (11), 838-846, 2007 | 369 | 2007 |
| Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ... Nature Cancer 1 (9), 873-881, 2020 | 307 | 2020 |
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib G Cusatis, V Gregorc, J Li, A Spreafico, RG Ingersoll, J Verweij, ... Journal of the National Cancer Institute 98 (23), 1739-1742, 2006 | 284 | 2006 |
| The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review FR Hirsch, A Spreafico, S Novello, MD Wood, L Simms, M Papotti Journal of Thoracic Oncology 3 (12), 1468-1481, 2008 | 280 | 2008 |
| A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer RMJM Van Geel, J Tabernero, E Elez, JC Bendell, A Spreafico, M Schuler, ... Cancer discovery 7 (6), 610-619, 2017 | 236 | 2017 |
| Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma M Oliva, A Spreafico, M Taberna, L Alemany, B Coburn, R Mesia, LL Siu Annals of oncology 30 (1), 57-67, 2019 | 207 | 2019 |
| Hyperprogressive disease in early‐phase immunotherapy trials: clinical predictors and association with immune‐related toxicities Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ... Cancer 125 (8), 1341-1349, 2019 | 143 | 2019 |
| Phase II study of asparagine-glycine-arginine–human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural … V Gregorc, PA Zucali, A Santoro, GL Ceresoli, G Citterio, TM De Pas, ... Journal of Clinical Oncology 28 (15), 2604-2611, 2010 | 141 | 2010 |
| Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. F Meric-Bernstam, SK Sandhu, O Hamid, A Spreafico, S Kasper, ... Journal of Clinical Oncology 37 (15_suppl), 2507-2507, 2019 | 140 | 2019 |
| Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 LT Nguyen, SD Saibil, V Sotov, MX Le, L Khoja, D Ghazarian, L Bonilla, ... Cancer Immunology, Immunotherapy 68, 773-785, 2019 | 126 | 2019 |
| Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J Tabernero, RV Geel, TK Guren, RD Yaeger, A Spreafico, JE Faris, ... Journal of Clinical Oncology 34 (15_suppl), 3544-3544, 2016 | 119 | 2016 |
| Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer JJ Tentler, S Nallapareddy, AC Tan, A Spreafico, TM Pitts, MP Morelli, ... Molecular cancer therapeutics 9 (12), 3351-3362, 2010 | 91 | 2010 |
| Genomic testing in cancer: patient knowledge, attitudes, and expectations PS Blanchette, A Spreafico, FA Miller, K Chan, J Bytautas, S Kang, ... Cancer 120 (19), 3066-3073, 2014 | 87 | 2014 |
| Impact of cisplatin dose intensity on human papillomavirus-related and-unrelated locally advanced head and neck squamous cell carcinoma A Spreafico, SH Huang, W Xu, R Granata, CS Liu, JN Waldron, E Chen, ... European Journal of Cancer 67, 174-182, 2016 | 85 | 2016 |
| Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer A Spreafico, JJ Tentler, TM Pitts, AC Tan, MA Gregory, JJ Arcaroli, ... Clinical Cancer Research 19 (15), 4149-4162, 2013 | 76 | 2013 |
| Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC) F Cappuzzo, S Bartolini, GL Ceresoli, S Tamberi, A Spreafico, ... British journal of cancer 90 (1), 82-86, 2004 | 75 | 2004 |
| Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity SY Cindy Yang, SC Lien, BX Wang, DL Clouthier, Y Hanna, I Cirlan, ... Nature communications 12 (1), 5137, 2021 | 69 | 2021 |
| Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib V Gregorc, M Hidalgo, A Spreafico, G Cusatis, V Ludovini, RG Ingersoll, ... Clinical Pharmacology & Therapeutics 83 (3), 477-484, 2008 | 64 | 2008 |
Lillian SiuPrincess Margaret Cancer CentreVerified email at uhn.ca
